Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tristan Penson

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Acta Neuropathologica Communications|October 19, 2018
TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutationsErik A Williams, Julie J Miller, Shilpa S Tummala, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2015
XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal CancerIsabel Ferreiro-Neira, Nancy E Torres, Lukas F Liesenfeld, et al.
Journal of Medical Virology|January 15, 2022
Post-sequelae symptoms and comorbidities after COVID-19Priya Duggal, Tristan Penson, Hannah N Manley, et al.
Journal of Neuro-Oncology|December 12, 2018
Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groupsTareq A Juratli, Shilpa S Tummala, Angelika Riedl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2019
The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in <i>PIK3CA</i>-Mutant Breast Cancer Brain MetastasesFranziska M Ippen, Christopher A Alvarez-Breckenridge, Benjamin M Kuter, et al.
Oncotarget|January 10, 2018
Intratumoral heterogeneity and <i>TERT</i> promoter mutations in progressive/higher-grade meningiomasTareq A Juratli, Christian Thiede, Mara V A Koerner, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 8, 2018
Genotype-targeted local therapy of gliomaGanesh M Shankar, Ameya R Kirtane, Julie J Miller, et al.
Acta Neuropathologica|August 21, 2018
DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcomeTareq A Juratli, Devin McCabe, Naema Nayyar, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Acta Neuropathologica Communications|October 19, 2018
TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutationsErik A Williams, Julie J Miller, Shilpa S Tummala, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2015
XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal CancerIsabel Ferreiro-Neira, Nancy E Torres, Lukas F Liesenfeld, et al.
Journal of Medical Virology|January 15, 2022
Post-sequelae symptoms and comorbidities after COVID-19Priya Duggal, Tristan Penson, Hannah N Manley, et al.
Journal of Neuro-Oncology|December 12, 2018
Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groupsTareq A Juratli, Shilpa S Tummala, Angelika Riedl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2019
The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in <i>PIK3CA</i>-Mutant Breast Cancer Brain MetastasesFranziska M Ippen, Christopher A Alvarez-Breckenridge, Benjamin M Kuter, et al.
Oncotarget|January 10, 2018
Intratumoral heterogeneity and <i>TERT</i> promoter mutations in progressive/higher-grade meningiomasTareq A Juratli, Christian Thiede, Mara V A Koerner, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 8, 2018
Genotype-targeted local therapy of gliomaGanesh M Shankar, Ameya R Kirtane, Julie J Miller, et al.
Acta Neuropathologica|August 21, 2018
DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcomeTareq A Juratli, Devin McCabe, Naema Nayyar, et al.
Pageof 1